The global circulating tumor cells market is anticipated to expand at substantial CAGR during the forecast period, between 2020 and 2027. Adoption of new technology, advancements in biotechnology and bioengineering technology for the detection of diseases, and rising demand for companion diagnostics are driving the growth of the global circulating tumor cells market.
Circulating tumor cells are tumor cells, which have shed from primary tumor and circulate in the body through blood circulation.Circulating tumors are used for the detection of cancer and to analyze the progression of the disease. Tumor markers are used with circulating tumors for the diagnosis of cancer.
Attributes | Details |
Base Year | 2019 |
Historic Data | 2017 & 2018 |
Forecast Period | 2020–2027 |
Regional Scope | Asia Pacific, North America, Europe, Latin America, and Middle East & Africa |
Report Coverage | Market scope, analysis, share, competitive analysis, growth facts, restraints, opportunities, and revenue forecast |
The report on the globalcirculating tumor cells market includes an assessment of the market, size, share, trends, segments, and regional markets. Overview and dynamics have been included in the report.
The CTC enrichment methods segment is projected to hold a significant share of the market
Based on technology, the circulating tumor cells market can be segmented into CTC enrichment methods and CTC detection methods. The CTC enrichments methods segment is sub-segmented into positive enrichment, negative enrichment, and others.The CTC detection methods segment is further divided into immunocytochemical technology, molecular RNA based technology, and others. The negative enrichment method sub-segment of the CTC enrichments methods segment is projected to grow at a significant pace during the forecast period. Negative enrichment methods are used for the isolation of the circulating tumors. Conversely, the immunocytochemical technology segment is anticipated to expand at a significant CAGR between 2020 and 2027.
The multiple chromosome abnormalities segment to hold significant market share
On the basis of applications, the market can be segregated into multiple chromosome abnormalities, RNA profiling, protein expression, cellular communication, and others.The multiple chromosome segment is projected to constitute a significant share of the market during the forecast period. Rising prevalence of multiple chromosome abnormality syndromes is expected to drive the growth of the segment.
The devices or systems segment is expected to grow at a rapid pace during the forecast period
In the terms of products, the circulating tumor cells products market can be fragmented into kits and reagents, blood collection tubes, and devices or systems. The kits and reagents segment is projected to grow at a significant pace during the forecast period, due tothe availability of a wide range of products. Growing use of devices or systems for the detection of cancer cells is expected to propel the market.
The blood segment to grow during the forecast period
Based on tumor cells specimens, the market can be classified as blood, bone marrow, and other body fluids. The blood segment is expected to hold a significant share of the market during the forecast period. Blood samples are used for the prognosis of diseases.High throughput techniques are used for the detection of genomes in the blood samples, thereby driving the segment.
North America dominates the global market
On the basis of regions, the global circulating tumor cells market can be categorized as North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America accounts for a considerable share of the global market. The US is expected to account for a significant share of the market during the forecast period, owing to the presence of advanced healthcare infrastructure and skilled professionals in the country. Increasing prevalence of cancer in the US is propelling the growth of the market in the region.
By Technology
Key players in the global circulating tumor cells market includeAviva Biosciences, Advanced Cell Diagnostics Inc., Biocept Inc., LungLife AI Inc., Creatv Micro Tech, Inc., Miltenyi Biotec, Menarini Silicon Biosystems, Precision for Medicine,, and Qiagen NV. They engage in mergers & acquisitions, collaborations, agreements, and partnerships to strengthen their geographical presence and market share.
Some other reports from this category!